AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19913781
Drug: Online problem-solving
RxNorm normalized name: Solv X
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online problem-solving therapy (PST)
Trial: 16364838
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg/day
Trial: 16364838
Drug: Bendroflumethiazide 2.5
RxNorm normalized name: bendroflumethiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 2.5 mg/day
Trial: 16364838
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg/day (for resistant hypertension)
Trial: 11850256
Drug: Caspofungin 5
RxNorm normalized name: caspofungin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 5 to 100 mg (single-dose)
Trial: 11850256
Drug: Caspofungin 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 15 mg daily (multiple-dose)
Trial: 11850256
Drug: Caspofungin 50
RxNorm normalized name: caspofungin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 50 mg daily (multiple-dose)
Trial: 11850256
Drug: Caspofungin 70
RxNorm normalized name: caspofungin 70 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 70 mg daily (multiple-dose)
Trial: 11850256
Drug: Caspofungin 50
RxNorm normalized name: caspofungin 50 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 50 mg daily without loading dose (multiple-dose)
Trial: 11850256
Drug: Caspofungin 70
RxNorm normalized name: caspofungin 70 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caspofungin 70 mg daily (3-week study)
Trial: 8572837
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of losartan potassium and 12.5 mg of hydrochlorothiazide
Trial: 1956528
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution 2 (CE2)
Trial: 1956528
Drug: Carbohydrate-electrolyte solution
RxNorm normalized name: CARBOHYDRATE/ELECTROLYTES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate-electrolyte solution 1 (CE1)
Trial: 6129886
Drug: Non-selective beta-adrenoceptor
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-selective beta-adrenoceptor blocker propranolol
Trial: 6129886
Drug: Selective beta-adrenoceptor
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective beta-adrenoceptor blocker metoprolol
Trial: 26049533
Drug: Electronic interactive
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electronic interactive tablet intervention
Trial: 22031171
Drug: Atorvastatin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (10 or 20 mg/day depending on weight)
Trial: 19539430
Drug: Platinum chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum chemotherapy regimens
Trial: 19539430
Drug: Taxane chemotherapy
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane chemotherapy regimens
Trial: 19539430
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of platinum and taxane chemotherapy regimens
Trial: 19539430
Drug: Monotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy with an agent other than platinum or taxane
Trial: 14678347
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (1200 microg)
Trial: 12231083
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg once daily
Trial: 12231083
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg twice daily
Trial: 12231083
Drug: Furosemide 40
RxNorm normalized name: furosemide 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 40 mg once daily (2-week treatment)
Trial: 12231083
Drug: Captopril 12.5
RxNorm normalized name: captopril 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 12.5 mg twice daily (2-week treatment)
Trial: 8008342
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) injections (5 mg, five injections over 2 weeks post-surgery)
Trial: 8008342
Drug: 5-Fluorouracil (5-FU)
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-Fluorouracil (5-FU) injections
Trial: 8008342
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no injections)
Trial: 24549160
Drug: Tiotropium bromide
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide (18 μg) once daily inhaled capsule
Trial: 21986341
Drug: Cognitive rehabilitation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive rehabilitation (CR) intervention comprising 12 individual weekly sessions
Trial: 18574929
Drug: Therapy for
RxNorm normalized name: nutritional therapy for GSD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy for early stage patients
Trial: 18574929
Drug: Antiparkinsonian therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiparkinsonian therapy for late stage patients
Trial: 15160570
Drug: Topical placental
RxNorm normalized name: human placental tissue preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placental extract
Trial: 11219875
Drug: Conventional analgesic
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional analgesic management
Trial: 29952641
Drug: Midazolam (0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.04 mg/kg) with propofol
Trial: 21163585
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser (LLL) therapy 2.5 J/cm(2)
Trial: 15356829
Drug: Amprenavir-ritonavir (APV-RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir-ritonavir (APV-RTV) 600/100 mg b.i.d.
Trial: 15356829
Drug: Amprenavir-ritonavir (APV-RTV)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir-ritonavir (APV-RTV) 1200/200 mg q.d.
Trial: 15356829
Drug: Both regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both regimens (APV-RTV 600/100 mg b.i.d. and APV-RTV 1200/200 mg q.d.)
Trial: 9926292
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 5g daily for 4 weeks
Trial: 9926292
Drug: Antacids for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antacids for 4 weeks (Control)
Trial: 2831525
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of enalapril
Trial: 2831525
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of enalapril (after dosage increase)
Trial: 2831525
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of atenolol (after dosage increase)
Trial: 31990730
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing for 2 minutes before induction of anesthesia (group G)
Trial: 31990730
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (group C) asked to swallow twice without additional treatment
Trial: 31990730
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (group G)
Trial: 31990730
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (group G) in patients with bloody SGA devices
Trial: 31990730
Drug: Gum chewing
RxNorm normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gum chewing (group G) in patients without bloody SGA devices
Trial: 29358539
Drug: 625 mg
RxNorm normalized name: betaine 625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625 mg of combined amoxicillin and clavulanic acid tablet
Trial: 29358539
Drug: 625 mg
RxNorm normalized name: betaine 625 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625 mg of combined amoxicillin and clavulanic acid tablet + 400 mg metronidazole tablet
Trial: 18412944
Drug: Real rTMS
RxNorm normalized name: REAL FOODS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Real rTMS treatment (1 Hz for 2 weeks)
Trial: 16485876
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) with topical 5‐aminolevulinic acid (ALA), treated 4 times weekly with 30‐minute ALA incubation and blue light activation.
Trial: 16485876
Drug: Topical clindamycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical clindamycin, used as control treatment.
Trial: 10426835
Drug: Ambulatory intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory intermittent dobutamine infusion at 2.5 microgram/kg/min for 48 hours/week for 6 months
Trial: 10426835
Drug: Optimal standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimal standard treatment (control group)
Trial: 9136493
Drug: Methylphenidate 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate 0.1 mg/kg
Trial: 7372783
Drug: Intravenous beta-endorphin
RxNorm normalized name: beta-endorphin human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous beta-endorphin infusion
Trial: 26353829
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin D supplementation (1,600 IU/day for <1 year old, 2,400 IU/day for >1 year old)
Trial: 23368915
Drug: ω‐3 polyunsaturated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω‐3 polyunsaturated fatty acids (PUFAs) supplemented parenteral nutrition (PN)
Trial: 23368915
Drug: Isocaloric and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric and isonitrogenous parenteral nutrition (PN) without ω‐3 PUFAs
Trial: 21269649
Drug: Mitral valve
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitral valve surgery with implantation of the CorCap cardiac support device (treatment group)
Trial: 19149978
Drug: Doxycycline (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (100 mg/day for 6 weeks) followed by Ivermectin (150 microg/kg orally)
Trial: 11208636
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate (FP) 500 microg twice daily
Trial: 9033439
Drug: Salmeterol 21
RxNorm normalized name: SALMETEROL 21MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 21 micrograms twice daily
Trial: 8331545
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of APD over 4 h
Trial: 8331545
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg of APD over 24 h
Trial: 16237386
Drug: estradiol (Estrofem;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: estradiol (Estrofem; 2 mg)
Trial: 16237386
Drug: buspirone (Buspar;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buspirone (Buspar; 5 mg)
Trial: 15504379
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion (600 mg mifepristone and 1 mg gemeprost)
Trial: 10843450
Drug: Prazosin 0.5
RxNorm normalized name: prazosin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin 0.5 mg twice daily
Trial: 10843450
Drug: Terazosin 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terazosin 0.5 mg twice daily
Trial: 10843450
Drug: Tamsulosin 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin 0.1 mg once daily
Trial: 3100464
Drug: Oral prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prostaglandin E1 (PGE1) analogue
Trial: 2839813
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine MMU 18006 (10^5, 10^4, or 10^3 plaque-forming units)
Trial: 2839813
Drug: Rhesus rotavirus
RxNorm normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhesus rotavirus vaccine MMU 18006
Trial: 14558397
Drug: Topical 20%
RxNorm normalized name: urea topical 20% topical foam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 20% 5-aminolevulinic acid (5-ALA) followed by 595 nm pulsed dye laser (PDL) irradiation
Trial: 14558397
Drug: Pulsed dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed dye laser (PDL) treatment alone or untreated lesions
Trial: 3804884
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 g intravenously every 12 h for mean duration 8.7 days)
Trial: 3804884
Drug: Cefamandole (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefamandole (1.5 g intravenously every 6 h for mean duration 8.2 days)
Trial: 30839013
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (FO, n = 35, 2 g day‐1 eicosapentaenoic acid + docosahexaenoic acid)
Trial: 30839013
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil (FLO, n = 39, 2.5 g day‐1 α‐linolenic acid)
Trial: 28335886
Drug: OxCapRT (oxaliplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OxCapRT (oxaliplatin 85 mg/m2 day 1, 15, 29; capecitabine 625 mg/m2 bd on days of radiotherapy)
Trial: 28335886
Drug: CarPacRT (carboplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CarPacRT (carboplatin AUC2; paclitaxel 50 mg/m2 day 1, 8, 15, 22, 29)
Trial: 24595578
Drug: Ivermectin 1%
RxNorm normalized name: IVERMECTIN 1% CREAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 1% cream
Trial: 19208350
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg/day for 1 month (increased to 40 mg/day at day 15)
Trial: 19208350
Drug: Simvastatin with
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin with beta-adrenergic blockers
Trial: 19208350
Drug: Simvastatin without
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simvastatin without beta-adrenergic blockers
Trial: 9469328
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA) 160 mg
Trial: 2120639
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg h‐1 intra‐arterial rt‐PA
Trial: 2120639
Drug: 5000 units
RxNorm normalized name: A-25, 25000 units oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5000 units h‐1 Sk and 250 units h‐1 heparin intra‐arterially
Trial: 224083
Drug: Stannous fluoride
RxNorm normalized name: Stannous Fluoride
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Stannous fluoride dentifrice in a silica gel base
Trial: 29967948
Drug: Deep neuromuscular
RxNorm normalized name: Deep Sea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep neuromuscular blockade (NMB) with 4 mg/kg sugammadex at post-tetanic count (PTC) of 2
Trial: 29967948
Drug: Moderate neuromuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate neuromuscular blockade (NMB) with 2 mg/kg sugammadex at a train-of-four (TOF) count of 1 or 2
Trial: 28854592
Drug: Weight reduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight reduction intervention followed by IVF treatment; 12 weeks of low calorie liquid formula diet (LCD) of 880 kcal/day followed by weight stabilization for 2-5 weeks.
Trial: 28854592
Drug: IVF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVF treatment only.
Trial: 11480656
Drug: Cognitive-behavioral insomnia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral insomnia therapy (CBT)
Trial: 9926274
Drug: salbutamol 8
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 8 mg
Trial: 1687425
Drug: pindolol 10
RxNorm normalized name: pindolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pindolol 10 mg
Trial: 3058043
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin 2 (IL2) administered intravenously at doses of 1 x 10(4), 3.3 ‐ 5 x 10(4), 1 x 10(5), 3.3‐5 x 10(5), 1 x 10(6) and 3.3 x 10(6) U/day
Trial: 3058043
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human interleukin 2 (IL2) administered subcutaneously at a dose of 1 x 10(6) U/day for 5 days
Trial: 25403646
Drug: LCZ696 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCZ696 (400 mg daily)
Trial: 19061537
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray (FFNS), 110 microg/day, once daily
Trial: 19061537
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate nasal spray (FPNS), 200 microg/day, twice daily
Trial: 16505427
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 40,000 U subcutaneously weekly (40K arm)
Trial: 15284376
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of elemental iron alone
Trial: 15284376
Drug: 10 mg/d
RxNorm normalized name: Arixtra 10 mg/dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/d of elemental iron in combination with multimicronutrients
Trial: 11052409
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) at a mean dose of 80 mg (1.8 mg/kg/day) during the open phase
Trial: 11052409
Drug: Nortriptyline (NT)
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nortriptyline (NT) during the discontinuation phase
Trial: 11052409
Drug: Placebo during
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo during the discontinuation phase
Trial: 9333770
Drug: TSH-receptor antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TSH-receptor antibodies (TRAb) detection
Trial: 9333770
Drug: Thyroperoxidase antibodies
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroperoxidase antibodies (TPO‐Ab) estimation
Trial: 9333770
Drug: Thyrostatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyrostatic treatment of Graves' disease
Trial: 8039151
Drug: CEF with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEF with G-CSF
Trial: 20707790
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride 60 mg extended release (ER)
Trial: 16549856
Drug: PSA threshold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PSA threshold below 4.0 ng/mL
Trial: 8691967
Drug: d-sotalol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-sotalol (100 mg increased to 200 mg twice daily, if tolerated)
Trial: 1755948
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg)
Trial: 1755948
Drug: Chlorprothixene (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorprothixene (30 mg)
Trial: 1755948
Drug: Ketotifen (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketotifen (3 mg)
Trial: 27824277
Drug: Lactobacillus brevis
RxNorm normalized name: Lactobacillus brevis
DrugBank: Lactobacillus brevis (DB18532)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus brevis DSM17250 extract (ointment formulation)